[ad_1]
Bristol Myers Squibb will acquire radiopharmaceutical therapeutics company RayzeBio for $62.50 a share in cash.
Continue reading this article with a Barron’s subscription.
Source link
Source link
Source link
[ad_1]
Bristol Myers Squibb will acquire radiopharmaceutical therapeutics company RayzeBio for $62.50 a share in cash.
Continue reading this article with a Barron’s subscription.
